MDXG vs. NARI, IRTC, PRCT, NVST, TMDX, SLNO, LIVN, ENOV, NVCR, and WRBY
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
MiMedx Group vs.
MiMedx Group (NASDAQ:MDXG) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
In the previous week, MiMedx Group had 10 more articles in the media than Inari Medical. MarketBeat recorded 10 mentions for MiMedx Group and 0 mentions for Inari Medical. MiMedx Group's average media sentiment score of 1.12 beat Inari Medical's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media.
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 1.3% of MiMedx Group shares are held by insiders. Comparatively, 10.6% of Inari Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
MiMedx Group presently has a consensus price target of $12.00, suggesting a potential upside of 51.90%. Inari Medical has a consensus price target of $68.00, suggesting a potential downside of 14.97%. Given MiMedx Group's stronger consensus rating and higher probable upside, equities analysts plainly believe MiMedx Group is more favorable than Inari Medical.
MiMedx Group has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
MiMedx Group has higher earnings, but lower revenue than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
MiMedx Group has a net margin of 23.86% compared to Inari Medical's net margin of -13.68%. MiMedx Group's return on equity of 26.21% beat Inari Medical's return on equity.
Inari Medical received 20 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 82.14% of users gave MiMedx Group an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
Summary
MiMedx Group beats Inari Medical on 13 of the 18 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
This page (NASDAQ:MDXG) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy MDXG Stock Free MDXG Stock Alerts